ReviewAdvanced drug delivery reviews2006
Display technologies: application for the discovery of drug and gene delivery agents.
Review in Advanced drug delivery reviews, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 259 citations in OpenAlex.
- Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.ACS chemical biology · 2012Pooled it
- Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.Cancer · 2015Trial
- Open-Source DNA-Encoded Library informatics Package for Design, Decoding, and Analysis: DELi.bioRxiv : the preprint server for biology · 2025Article
- Nanocarriers for Delivery of Anticancer Drugs: Current Developments, Challenges, and Perspectives.Pharmaceutics · 2024Review
- A New Bacterial Chassis for Enhanced Surface Display of Recombinant Proteins.Cellular and molecular bioengineering · 2024Article
- Current advancements in B-cell receptor sequencing fast-track the development of synthetic antibodies.Molecular biology reports · 2024Review
- Development of an Anti-HER2 Single-Chain Variable Antibody Fragment Construct for High-Yield Soluble Expression inBiomolecules · 2023Article
- A 3D Peptide/[60]Fullerene Hybrid for Multivalent Recognition.Angewandte Chemie (International ed. in English) · 2022Article
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- Directing evolution of novel ligands by mRNA display.Chemical Society reviews · 2021Review
- GPCR-Based Bioactive Peptide Screening Using Phage-Displayed Peptides and an Insect Cell System for Insecticide Discovery.Biomolecules · 2021Article
- Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis.Polymers · 2020Review
- High-throughput identification of peptide agonists against GPCRs by co-culture of mammalian reporter cells and peptide-secreting yeast cells using droplet microfluidics.Scientific reports · 2019Article
- Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Article
- Article
- Protein engineering approaches for antibody fragments: directed evolution and rational design approaches.Turkish journal of biology = Turk biyoloji dergisi · 2019Article
- Quantitative PCR of T7 Bacteriophage from Biopanning.Journal of visualized experiments : JoVE · 2018Article
- Accelerating Patients' Access to Advanced Therapies in the EU.Molecular therapy. Methods & clinical development · 2017Review
- Drug delivery vectors based on filamentous bacteriophages and phage-mimetic nanoparticles.Drug delivery · 2017Review
- Virus-Derived Peptides for Clinical Applications.Chemical reviews · 2017Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Recognition of molecular diversity of cell surface proteomes in disease is essential for the development of targeted therapies. Progress in targeted therapeutics requires establishing effective approaches for high-throughput identification of agents specific for clinically relevant cell surface markers. Over the past decade, a number of platform strategies have been developed to screen polypeptide libraries for ligands targeting receptors selectively expressed in the context of various cell surface proteomes. Streamlined procedures for identification of ligand-receptor pairs that could serve as targets in disease diagnosis, profiling, imaging and therapy have relied on the display technologies, in which polypeptides with desired binding profiles can be serially selected, in a process called biopanning, based on their physical linkage with the encoding nucleic acid. These technologies include virus/phage display, cell display, ribosomal display, mRNA display and covalent DNA display (CDT), with phage display being by far the most utilized. The scope of this review is the recent advancements in the display technologies with a particular emphasis on molecular mapping of cell surface proteomes with peptide phage display. Prospective applications of targeted compounds derived from display libraries in the discovery of targeted drugs and gene therapy vectors are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.